Skip to content

Performance of a New Glucose Meter System

Performance of the TATSU/Tradewind Blood Glucose Monitoring System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01264016
Enrollment
96
Registered
2010-12-21
Start date
2010-11-30
Completion date
2010-12-31
Last updated
2016-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The purpose of this study is to evaluate the performance and acceptability of a new blood glucose monitoring system, which includes meter and sensor strip.

Interventions

Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.

Sponsors

Ascensia Diabetes Care
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 1 or 2 diabetes * Age 18 years or older * Routinely performs blood glucose self testing at home, at least once per day * Able to speak, read, and understand English. * Is willing to complete all study procedures

Exclusion criteria

* Currently pregnant * Hemophilia or any other bleeding disorder * Taking prescription anticoagulants or has clotting problems that may prolong bleeding. Taking aspirin daily is not excluded * Subject employee of competitive medical device company * Cognitive disorder or other condition, which in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study

Design outcomes

Primary

MeasureTime frameDescription
Percent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method2 hoursSubjects with diabetes used an investigational blood glucose monitoring system (BGMS) with subject capillary blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results \<75mg/dL) or +/- 5 to 20% (for reference BG results \>=75mg/dL) of the reference method results.
Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method2 hoursHealthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results \<75mg/dL) or +/- 5% to 20% (for reference BG results \>=75mg/dL) of the reference method results.

Secondary

MeasureTime frameDescription
Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)2 hoursSubjects reviewed the instructions for use (User Guide and Quick Reference Guide) to learn to use the system. Study staff then observed and rated the subjects (1 to 4) on their success at performing five tasks. Scale: 1.Success in performing tasks correctly without assistance. 2.Successful with additional review of User Guide. 3.Successful with additional review and study staff assist similar to review of a specific function during a Customer Service call. 4.Subject did not perform task correctly and study staff intervention was required.

Countries

United States

Participant flow

Participants by arm

ArmCount
Intended Users of the Monitoring System
Untrained subjects with diabetes use an investigational blood glucose monitoring system. One subject withdrew voluntarily; one subject was withdrawn. One subject hematocrit measurement was missing so subject data was not evaluable.
93
Total93

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyFelt faint at sight of blood1
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicIntended Users of the Monitoring System
Age, Continuous
Mean age (range of ages)
37.8 years
Region of Enrollment
United States
93 participants
Sex: Female, Male
Female
47 Participants
Sex: Female, Male
Male
46 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
13 / 96
serious
Total, serious adverse events
0 / 96

Outcome results

Primary

Percent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method

Subjects with diabetes used an investigational blood glucose monitoring system (BGMS) with subject capillary blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results \<75mg/dL) or +/- 5 to 20% (for reference BG results \>=75mg/dL) of the reference method results.

Time frame: 2 hours

Population: One subject did not complete capillary blood testing (low blood sugar) and one subject hematocrit measurement was missing. These subjects' blood test data was not evaluable. Since the remaining 92 subjects tested 2 test strip lots on the BGM system, 2x92(184) tests results were possible.

ArmMeasureGroupValue (NUMBER)
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 20mg/dL (<75mg/dL BG)100.0 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 20mg/dL (>=75mg/dL BG)100.0 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 15mg/dL (<75 mg/dL BG)100.0 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 15mg/dL (>=75 mg/dL BG)100.0 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 10mg/dL (<75 mg/dL BG)100.0 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 10mg/dL (>=75 mg/dL BG)98.2 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 5mg/dL (<75 mg/dL BG)80.0 percentage of BG Results
Intended Users of the Monitoring SystemPercent of Capillary Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 5mg/dL (>=75 mg/dL BG)75.0 percentage of BG Results
Primary

Percent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method

Healthcare professionals (study staff) used an investigational blood glucose monitoring system (BGMS) with subject venous blood. BGM results were compared to a reference lab glucose method - Yellow Springs Instrument (YSI) Analyzer. BG results were used to calculate the number of BG results within +/- 5 to 20 mg/dL (for reference BG results \<75mg/dL) or +/- 5% to 20% (for reference BG results \>=75mg/dL) of the reference method results.

Time frame: 2 hours

Population: One subject's hematocrit measurement was missing, so this subject's blood test data was not evaluable. Since study staff tested each subject's venous blood using 2 lots of test strips, 2x93(or 186) test results were possible.

ArmMeasureGroupValue (NUMBER)
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 20mg/dL (<75mg/dL bg)100.0 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 20mg/dL (>=75mg/dL bg)100.0 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 15mg/dL (<75mg/dL bg)100.0 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 15mg/dL (>=75mg/dL bg)100.0 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 10mg/dL (<75mg/dL bg)100.0 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 10mg/dL (>=75mg/dL bg)98.8 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 5mg/dL (<75mg/dL bg)87.5 percentage of venous bg results
Intended Users of the Monitoring SystemPercent of Venous Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method% within 5mg/dL (>=75mg/dL bg)82.9 percentage of venous bg results
Secondary

Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)

Subjects reviewed the instructions for use (User Guide and Quick Reference Guide) to learn to use the system. Study staff then observed and rated the subjects (1 to 4) on their success at performing five tasks. Scale: 1.Success in performing tasks correctly without assistance. 2.Successful with additional review of User Guide. 3.Successful with additional review and study staff assist similar to review of a specific function during a Customer Service call. 4.Subject did not perform task correctly and study staff intervention was required.

Time frame: 2 hours

Population: Per protocol

ArmMeasureGroupValue (NUMBER)
Intended Users of the Monitoring SystemNumber of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)Turn meter on/off94 participants
Intended Users of the Monitoring SystemNumber of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)Date and Time Set on Meter92 participants
Intended Users of the Monitoring SystemNumber of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)Normal Control Testing94 participants
Intended Users of the Monitoring SystemNumber of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)Subject blood testing94 participants
Intended Users of the Monitoring SystemNumber of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)Understand underfill icon/ability to apply more bl94 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026